Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05277350 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
A Phase 1 study of Bloodstream Infection and E.Coli Infections, sponsored by SNIPR Biome Aps..
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05277350 is a Phase 1 study of Bloodstream Infection and E.Coli Infections that has completed, run by SNIPR Biome Aps.. The registered enrollment target is 36 participants, below the 77-participant average among 3 other Bloodstream Infection trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05277350, a Phase 1 study of Bloodstream Infection and E.Coli Infections, has completed, sponsored by SNIPR Biome Aps..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administrations of SNIPR001.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SNIPR001
Study Locations (1)
Ohio
- Medpace Clinical Pharmacology - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2023-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05277350
The ClinicalTrials.gov registry entry for NCT05277350 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 3 other Bloodstream Infection trials with a reported enrollment target (53% lower). The listed sponsor is SNIPR Biome Aps., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bloodstream Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05277350 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05277350 about?
NCT05277350 is a clinical study titled "A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects". This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administrations of SNIPR001.
What is the current status of trial NCT05277350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-03-24. Estimated completion is 2023-05-01.
What conditions does trial NCT05277350 study?
This clinical trial studies the following conditions: Bloodstream Infection, E.Coli Infections.
What interventions are being tested in trial NCT05277350?
The interventions under investigation include: Placebo (DRUG), SNIPR001 (DRUG).
Who is sponsoring clinical trial NCT05277350?
This trial is sponsored by SNIPR Biome Aps., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05277350 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bloodstream Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.